Abstract
To accurately characterize the pathophysiology and proliferating activity of oligodendrogliomas, we studied cerebral blood flow and metabolism using positron emission tomography (PET) in five patients with this tumor. Regional cerebral blood flow (rCBF), cerebral blood volume (rCBV), oxygen extraction fraction (rOEF), and cerebral metabolic rates of oxygen (rCMRO2) and of glucose (rCMRGl) were quantitatively measured in tumor lesions and the contralateral gray matter. rCMRGl was analyzed based on both kinetic and autoradiographic methods. Tumor rCBF and rCBV were lower than in the contralateral gray matter in all preoperatively examined patients. Oxygen metabolism, determined by rCMRO2 and rOEF, was consistently reduced in the tumor (rCMRO2, P<0.05 vs. gray matter, determined by the Student's t-test). Tumor rCMRGl was significantly lower than the gray matter rCMRGl in both kinetic (P<0.01) and autoradiographic (P<0.05) analyses. Kinetic tumor rCMRGl varied between 1.22 and 4.13 mg/100 ml/min, but was lower than the gray matter value in all patients. Autoradiographic tumor rCMRGl, which ranged from 1.02 to 5.79 mg/100 ml/min, was also reduced in all tumors but one; the remaining tumor, which had a relatively high value of autoradiographic rCMRGl (comparable to gray matter rCMRGl), infiltrated the contralateral hemisphere through the corpus callosum, and was characterized by high cellular density. In one patient who suffered from tumor recurrence 8 years and 10 months after initial treatment, phosphorylation constant (K3) and kinetic rCMRGl of the recurring tumor were higher than those of the original tumor. No other tumors have regrown or recurred during the postoperative follow-up periods, which ranged from 22 to 130 months (median=101 months). Circulation and metabolism measured by PET provide in vivo biological characteristics, including proliferating activity, in oligodendrogliomas.
Similar content being viewed by others
References
Mørk SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J: Oligodendrogliom: incidence and biological behavior in a defined population. J Neurosurg 63: 881–889, 1985
Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19: 15–21, 1986
Wilkinson I, Anderson JR, Holmes AE: Oligodendroglioma: an analysis of 42 cases. J Neurol Neurosurg Psychiatry 50: 304–312, 1987
Nijjar TS, Simpson WJ, Gadalla T, McCartney M: Oligodendroglioma. The Princess Margaret Hospital Experience (1958–1984). Cancer 71: 4002–4006, 1993
Vonofakos D, Marcu H, Hacker H: Oligodendrogliomas: CT patterns with emphasis on features indicating maliganacy. J Comput Assist Tomogr 3: 783–788, 1979
Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ: Pediatric and adolescent oligodendrogliomas. AJNR 14: 1293–1300, 1993
DiChiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP: Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329, 1982
Mineura K, Yasuda T, Kowada M, Shishido T, Ogawa T, Uemura K: Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurol Res 8: 164–168, 1986
Kanno I, Miura S, Yamamoto S, Iida H, Murakami M, Takahashi K, Uemura K: Design and evaluation of a positron emission tomograph: Headtome III. J Comput Assist Tomogr 9: 931–939, 1985
Iida H, Miura S, Kanno I, Murakami M, Takahashi K, Uemura K, Hirose Y, Amano M, Yamamoto S, Tanaka K: Design and evaluation of Headtome IV, a whole-body positron emission tomography. IEEE Trans Nucl Sci 37: 1006–1010, 1989
Frackowiak RSJ, Lenzi GL, Jones T, Heather JD: Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 4: 727–736, 1980
Lammertsma AA, Jones T: Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 1. Description for the method. J Cereb Blood Flow Metab 3: 416–424, 1983
Sasaki H, Kanno I, Murakami M, Shishido F, Uemura K: Tomographic mapping of kinetic rate constants in the fluorodeoxyglucose model using dynamic positron emission tomography. J Cereb Blood Flow Metab 6: 447–454, 1986
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Topographic measurement of local cerebral glucose metabolic rate in human with 18F-2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 2: 371–388, 1979
Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, MacGregor RR, Shiue CY, Atkins H, Anand A, Dann R, Greenberg JH: Glucose metabolic rate kinetic model parameter determination in humans. The lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 5: 179–192, 1985
Mineura K, Sasajima T, Kowada M, Shishido F, Uemura K: Positron emission tomography (PET) study in patients with meningiomas. Brain Nerve 42: 145–151, 1990 (Japanese)
Lammertsma AA, Wise RJS, Cox TCS, Thomas DGT, Jones T: Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. Br J Radiol 58: 725–734, 1985
Patronas NJ, DiChiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816–822, 1985
Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M: Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62: 1074–1078, 1988
Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, Uemura K: Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 73: 2386–2394, 1994
DiChiro G, Hatazawa J, Katz DA, Rizzoli HV, DeMichele DJ: Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology 164: 521–526, 1987
Herholz K, Pietrzyk U, Voges J, Schr¨oder R, Halber M, Treuer H, Sturm V, Heiss WD: Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79: 853–858, 1993
Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, HansonMW, Burger PC, Herndon II JE, Meisler WJ, Schold SC: Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29: 347–355, 1991
Schifter T, Hoffman JM, Hanson MW, Boyko OB, Beam C, Paine S, Schold SC, Burger PC, Coleman RE: Serial FDGPET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17: 509–516, 1993
H¨olzer T, Herholz K, Jeske J, Heiss WD: FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17: 681–687, 1993
Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System, 2nd edn., Springer-Verlag, Berlin/Heidelberg, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mineura, K., Shioya, H., Kowada, M. et al. Blood Flow and Metabolism of Oligodendrogliomas: A Positron Emission Tomography Study with Kinetic Analysis of 18F-fluorodeoxyglucose. J Neurooncol 43, 49–57 (1999). https://doi.org/10.1023/A:1006296729019
Issue Date:
DOI: https://doi.org/10.1023/A:1006296729019